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Summary. Tissue factor (TF) pathway inhibitor I (TFPI) is the
physiological inhibitor of TF-induced blood coagulation.
Circulating blood contains full-length TFPI and TFPI trun-
cated at the C-terminal end. Previous studies have shown that
full-length TFPI exerts a stronger anticoagulant eﬀect on
diluted prothrombin time (DPT) than truncated TFPI, and it
has been suggested that full-length TFPI is biologically more
important in vivo. The objective of this studywas to develop and
validate an assay of TFPI anticoagulant activity. TFPI
anticoagulant activity was assayed using a modiﬁed DPT
assay. Plasmas were incubated in the absence and the presence
of TFPI-blocking antibodies. Results were expressed as a ratio
with the clotting time in the presence of anti-TFPI as the
denominator.The ratiowasnormalized against a ratioobtained
with a reference plasma.The assaywas comparedwith assays of
TFPI free antigen, total antigen, and bound TFPI, and TFPI
chromogenic substrate activity. We performed all tests in
436 healthy individuals. The normalized TFPI anticoagulant
ratio was strongly associated with TFPI free antigen (r ¼ 0.73)
but was weakly associated with TFPI chromogenic substrate
activity (r ¼ 0.46), TFPI total antigen (r ¼ 0.48), and bound
TFPI (r ¼ 0.30). TFPI chromogenic substrate activity was
strongly associatedwithTFPI total antigen (r ¼ 0.73).Wehave
developed a novel assay of TFPI anticoagulant activity in
plasma, which may be considered a functional assay of full-
length TFPI. Further studies are needed to establish the role of
TFPI anticoagulant activity for thrombotic disorders.
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Introduction
Coagulation is initiated when tissue factor (TF) gains access to
the circulating blood and forms a complex with zymogen
coagulation factor VII (FVII) or activated FVII (FVIIa). The
TF/FVIIa complex activates factor X (FX), and activated FX
(FXa) catalyzes the formation of thrombin from prothrombin.
TF/FVIIa catalytic activity is modulated by TF pathway
inhibitor (TFPI), which in a ﬁrst step binds to and inhibits
FXa, the TFPI/FXa complex then binds to and inhibits the
TF/FVIIa catalytic complex by forming a quaternary TFPI/
FXa/TF/FVIIa complex. Thus, TFPI functions as an inhibitor
of FXa as well as of TF/FVIIa [1].
There is now convincing evidence from in vitro and in vivo
experiments that TFPI plays an important role in regulating
the initiation of blood coagulation [2–7]. In man, some studies
have found that low levels of TFPI are a weak risk factor for
venous thrombosis [8–11]. However, manifest TFPI-deﬁciency,
either associated or not with thrombotic disorders, similar to
deﬁciencies of other coagulation inhibitors, have not yet been
detected [12]. One possible explanation for this apparent
discrepancy between the experimental evidence and data in
humans could be that current TFPI assays are technically
inadequate to detect the role of TFPI in vivo and thus to detect
TFPI deﬁciency [11,12].
The complex inhibitory mechanism, as well as the complex
distribution of TFPI in vivo, makes construction of an assay of
TFPI a challenging task. Amajor intravascular pool of TFPI is
free, full-length TFPI associated with the vascular endothelium
which may be released to the circulation by heparin and other
negatively charged ions. Although some free, full-length TFPI
is detected in circulating blood, most circulating TFPI
(80–95%) is truncated at the C-terminal and bound to
lipoproteins [13,14]. Small amounts of full-length TFPI are
also found in platelets.
TFPI bound to the endothelium is not readily assessed, but
circulating TFPImay be detected by different assays [15]. Most
commonly, TFPI is detected by commercially available enzyme
linked immunosorbent (ELISA) assays [9,11], which either
Correspondence: Anders E. A. Dahm, Ulleva˚l University
Hospital, Department of Hematology, N-0407 Oslo, Norway.
Tel.: +47 22119101; fax: +47 22119040; e-mail: a.e.a.dahm@medisin.
uio.no
Received 22 August 2004, accepted 10 December 2004
Journal of Thrombosis and Haemostasis, 3: 651–658
 2005 International Society on Thrombosis and Haemostasis
detect free, full-length TFPI or lipoprotein-associated TFPI.
TFPI activity assays are usually in-housemethods thatmeasure
the overall capacity of TFPI to inhibit TF/FVIIa catalytic
activity after prolonged incubation of TF/FVIIa with TFPI.
Residual TF/FVIIa after incubation with TFPI is determined
using an appropriate substrate, e.g. chromogenic substrates or
tritium-labeled FIX [16–19].
In contrast, TFPI activity may be determined as the ability
of TFPI to prolong clotting after the addition of a low
concentration of TF to plasma, i.e. assays based on the
diluted prothrombin time (DPT) [15]. Several in vitro studies
have shown that free, full-length TFPI has a much stronger
ability to prolong the clotting time than truncated TFPI or
lipoprotein-associated TFPI, even though their functional
chromogenic substrate activities are similar [20–23]. Since the
ability to prolong the clotting time might be considered
physiologically more important, it has been hypothesized that
free, full-length TFPI with strong anticoagulant activity is
more relevant for the function of TFPI in vivo [12,24].
Therefore, an assay for TFPI anticoagulant activity could be
a better assay of TFPI activity in vivo, and might potentially
be able to reveal TFPI deﬁciency states that other TFPI
assays cannot capture. However, methods for the assay of
plasma TFPI anticoagulant activity have not yet been
established.
In the present study we have established and validated a
method for the assay of TFPI anticoagulant activity based on a
modiﬁed DPT assay. The assay was validated against ELISAs
for TFPI free and total antigen, and against TFPI chromogenic
substrate activity, all recorded in plasma samples from the
Leiden Thrombophilia Study (LETS) [11].
Materials and methods
Reagents
Tris-buffered saline (TBS) was made to contain 0.05 mol L)1
Tris–HCl, 0.15 mol L)1 NaCl, at pH 7.4. Calcium chloride
(CaCl2) was diluted from 500 to 35 m mol L
)1 in TBS. TFwas
human recombinant, relipidated TF (DadeInnovin, Baxter
Diagnostics Inc.,Miami, FL,USA), which was diluted 1/200 in
TBS from stock solution. Anti-TFPI immunoglobulin (anti-
TFPI IgG) was puriﬁed polyclonal IgG raised against human
recombinantTFPI1)161 inagoatandwasakindgift fromDrPer
Østergaard, Novo-Nordisk, Gentofte, Denmark. Normal,
non-immune goat-IgG (sc-2028) was purchased from Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA. Full-length,
recombinant TFPI (rTFPI, Cat#4900ACT, recombinant active
human TFPI) was obtained from Amercian Diagnostica Inc,
Stamford, CT, USA. Truncated, rTFPI1)161 was a kind gift
from Dr Ole Nordfang, Novo-Nordisk, Denmark.
All blood samples were collected in Sarstedt Monovette
tubes (Sarstedt, Numbrecht, Germany) containing
0.106 mol L)1 trisodium citrate (0.1 vol), centrifuged for
10 min at 2000 · g at room temperature and stored in aliquots
at )70 C until assayed. Reference plasma was collected from
one healthy individual and a single batch was used for the
study.
Assay of TFPI anticoagulant activity
We used a DPT assay essentially as described previously by
other investigators [20,25,26] but modiﬁed as follows: 32 lL
plasma was incubated with 8 lL TBS or 8 lL anti-TFPI IgG
and incubated for 4–6 min at room temperature. Then, 30 lL
TF was added and the mixture was incubated for 3 min at
37 C. Finally, 30 lL 35 mmol L)1 CaCl2 was added and the
time to clotting was measured with a coagulometer (Amelung
KC4, Trinity Biotech, Bray, Ireland). To obtain a reasonable
difference in clotting time between plasmas with and without
anti-TFPI antibodies, we aimed to achieve a clotting time of the
reference plasma of approximately 75 s in the absence of anti-
TFPI IgG. This was achieved at 1/200-fold dilution of TF, i.e.
ﬁnal dilution 3/2000 in the assay. The concentration of anti-
TFPI IgG that completely inhibited the ability of TFPI to
prolong clotting was established by adding increasing concen-
trations of anti-TFPI IgG until the clotting time was no longer
shortened. The ﬁnal concentration used in the assaywas double
the maximum inhibiting concentration. Addition of anti-TFPI
IgG reduced clotting times by approximately 7–8 s in the
reference plasma. This shortening of clotting times after
blocking TFPI may be considered a measure of the ability of
TFPI in the sample to inhibit coagulation. The ability of anti-
TFPI IgG to neutralize TFPI was also tested using a
chromogenic substrate assay [19], in which these antibodies
were able to neutralize >95% of the chromogenic substrate
activity.
Test results were expressed as a TFPI anticoagulant ratio
with DPT in the absence of anti-TFPI IgG as the numerator
and DPT in the presence of TFPI blocking antibodies as the
denominator. To minimize the effects of variations in assay
conditions, e.g. day-to-day and batch-to-batch (of Innovin)
variations, both the anticoagulant ratios (and individual DPTs)
were normalized against the corresponding ratios and DPTs
obtained with the reference plasma. The normalized ratio was
called the normalized TFPI anticoagulant (n-TFPIac) ratio. A
low normalized ratio (< 1.0) indicates lowTFPI anticoagulant
activity, whereas a high ratio (> 1.0) indicates high TFPI
anticoagulant activity. As a result of the limited amounts of
plasma, most blood samples were only assayed in a single run.
The between-day coefﬁcient of variation (CV) was 2.8% and
within-day CV was between 0.5% and 1.5%.
Control experiments revealed that rapid freezing and
thawing for up to six cycles had a negligible effect on the test
results. Moreover, normal, non-speciﬁc goat-IgG had no effect
on clotting times.
Other TFPI assays
TFPI free antigen and TFPI total antigen were assayed in
duplicates with commercial ELISAs (AsserachromFree TFPI
and Asserachrom Total TFPI, Diagnostica Stago, Asnie`re,
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France) as described in detail elsewhere [11]. In both assays a
monoclonal antibody was used to catch TFPI. Two other
monoclonal antibodies conjugated with peroxidase were used
to detect either free, i.e. full-length TFPI, or total, i.e. full-
length and truncated and lipoprotein-associated TFPI. The
TFPI free antigen assay was speciﬁc for free, circulating, full-
length TFPI, and did not detect lipid-bound TFPI. The TFPI
total antigen assay detected the total amount of TFPI,
including full-length and truncated TFPI as well as lipid-
bound TFPI. Freeze-dried human plasmas containing known
amounts of TFPI that were provided in the kits were used for
calibration. Quality controls were performed using a control
specimen containing a high amount of TFPI as well as a sample
with a normal level of TFPI. Inter- and intra-assay variability,
measured as coefﬁcients of variation, was 4.4% and 2.9% for
TFPI total antigen, and 4.9% and 3.8% for TFPI free antigen,
respectively.
Bound TFPI was calculated as the difference between TFPI
total antigen and TFPI free antigen.
TFPI chromogenic substrate activity was assayed in
duplicate with a two-stage chromogenic substrate assay as
described earlier [19]. In this assay the TFPI activity was
determined by the quantiﬁcation of residual TF/FVIIa
catalytic activity after the incubation of diluted plasma
(containing TFPI) with TF, FVIIa in excess of TF binding
sites, and FXa. Inter- and intra-assay variabilities were 3.5%
and 1.4%, respectively.
Study population
In this study, we assayed blood samples collected from
control subjects in The Leiden Thrombophilia Study (LETS).
Details of study design and blood collection have been
described in detail elsewhere [27]. In short, LETS was a case–
control study with 474 patients with an objectively diagnosed
ﬁrst-time deep vein thrombosis and 474 sex- and age-matched
controls. Residual plasma samples were available from 436
individuals (183 men and 253 women). We have previously
reported that low levels of TFPI in this study, either of TFPI
free antigen, TFPI total antigen, or TFPI chromogenic
substrate activity, were associated with an increased risk of
deep vein thrombosis [11]. The patients were selected from
three anticoagulation clinics in the Netherlands, and the
controls were acquaintances of the patients or partners of
other patients. The Leiden University ethics committee
approved the study protocol, and all participants gave
informed consent to participate according to the Declaration
of Helsinki.
Statistical analysis
The association between the different TFPI assays and the
n-TFPIac ratio was studied in the controls because they
represent the general population. Three individuals with
extremely high n-TFPIac ratios were excluded from all
analyses, but are reported separately.
Data are reported as mean and standard deviation (SD).
Simple linear regression with TFPI chromogenic substrate
activity and n-TFPIac ratio as dependent variables was used to
estimate the association with the other TFPI assays and with
other coagulation factors. Normalized regression coefﬁcients
(z-score of the independent variable, i.e. the independent
variable expressed as a number of SD, negative or positive,
from the mean) were calculated for comparison of the different
regression coefﬁcients. Extreme outliers were excluded from the
regression analysis. All statistical analyses were executed using
the STATISTICAL PACKAGE FOR SOCIAL SCIENCES version 10
(SPSS Inc, Illinois, USA).
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Fig. 1. Eﬀect of full-length, recombinant TFPI (A) and recombinant
TFPI1)161 (B) on the normalized TFPI anticoagulant (n-TFPIac) ratio.
The x-axis shows the ﬁnal concentration of added recombinant TFPI in a
carrier-plasma.
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Results
In vitro effects of TFPI on n-TFPIac ratio
In vitro recovery experiments were performed using either full-
length rTFPI or truncated rTFPI1)161. These experiments
showed that increasing concentrations of full-length rTFPI
(0–34,7 ng mL)1) gave a corresponding linear increase in
n-TFPIac ratio, while truncated rTFPI1)161 (0–160 ng mL
)1)
essentially had no effect on the n-TFPIac ratio (Fig. 1).
Normalized TFPI anticoagulant ratio in vivo
The mean age of the study population was 47 years (range
16–73 years). The n-TFPIac ratio was approximately nor-
mally distributed as determined by inspecting the histogram
(Fig. 2). Mean n-TFPIac ratio was 1.03 (SD 0.066) with a
range from 0.87 to 1.22. Three individuals had extremely high
ratios (1.37, 1.41, and 1.85). These individuals also had
elevated levels of TFPI antigen or chromogenic substrate
activity. They were obvious outliers and consequently were
excluded from the analyses. Other coagulation factors, i.e.
ﬁbrinogen, prothrombin, FV, FVII, FVIII, FIX, FX, FXI,
protein S, and TAFI, and age had no or only a marginal effect
on the n-TFPIac ratio.
The effects of plasma TFPI on the DPT
Normalized DPT (n-DPT), reﬂecting the prolongation in
clotting times induced by plasma TFPI, was associated with
plasma TFPI levels. This association was strongest for TFPI
free antigen, and weakest for TFPI total antigen and bound
TFPI (Fig. 3A–C). In the absence of TFPI, i.e. after the
addition of anti-TFPI IgG, there were no clear associations
between n-DPT and any of the TFPI assays (Fig. 3D–F).
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Fig. 2. Distribution of normalized TFPI anticoagulant (n-TFPIac)
ratio in 436 individuals. Three individuals with TFPI anticoagulant ratios
of 1.37, 1.41, and 1.85 were excluded.
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Fig. 3. Scatter plots with linear regression lines showing TFPI free antigen, TFPI total antigen, and bound TFPI as determinants of the normalized
DPT (n-DPT). (A)–(C): the absence (–) of anti-TFPI IgG; (D)–(F): the presence (+) of anti-TFPI IgG.
654 A. E. A. Dahm et al
 2005 International Society on Thrombosis and Haemostasis
Determinants of n-TFPIac ratio
TFPI free antigen was a stronger determinant of the n-TFPIac
ratio than TFPI total antigen, TFPI chromogenic substrate
activity, and bound TFPI (Fig. 4 and Table 1). Bound TFPI
had the weakest association to the n-TFPIac ratio, while TFPI
total antigen and TFPI chromogenic substrate activity had an
intermediate and quite similar association to the n-TFPIac
ratio.
Determinants of TFPI chromogenic substrate activity
TFPI total antigen and bound TFPI had approximately the
same degree of association to TFPI chromogenic substrate
activity. Both were stronger determinants of TFPI chromo-
genic substrate activity than TFPI free antigen (Fig. 5 and
Table 2).
Discussion
In this study, we have tested a novel assay of TFPI
anticoagulant activity in plasma. The assay is based on the
ability of TFPI in plasma to prolong clotting time using a DPT
assay essentially as described by other investigators [20,25,26].
However, in the present report TFPI anticoagulant activity
was expressed as the ratio of DPT in plasma recorded in the
presence of TFPI, i.e. after preincubation with buffer, to the
DPT determined in the absence of TFPI, i.e. after preincuba-
tion with TFPI blocking antibodies. This ratio was normalized
against a ratio obtained with a reference plasma to minimize
variations of assay conditions. The assay was reproducible
with intra- and interassay coefﬁcients less than 3%, and
showed a clear dose–response relationship for full-length
rTFPI (but not rTFPI1)161) added in vitro. Finally, the assay
was validated against currently available antigen and func-
tional assays.
We have found that n-TFPIac ratio is strongly related to
TFPI free antigen, i.e. free, full-length TFPI, in plasma, but not
with TFPI chromogenic substrate activity, TFPI total antigen
or bound TFPI. These results are strongly supported by the
in vitro recovery experiments which demonstrated that the
assay was highly sensitive to full-length rTFPI, but was not
inﬂuenced by truncated TFPI (rTFPI1)161). The n-TFPIac
ratio may therefore be considered a functional assay of free,
full-length TFPI, and would potentially allow detection of
functionally abnormal TFPI molecules. Our ﬁndings corro-
borate previous studies showing that free, full-length TFPI
exerts a much stronger anticoagulant effect in DPT assays than
truncated or lipoprotein-associated TFPI at concentrations
with nearly identical chromogenic substrate activities [20–23],
and that the C-terminal end is vital for the anticoagulant
activity in DPT-based assays [28–30]. We have also found that
TFPI chromogenic substrate activity is mainly associated with
bound or lipoprotein-associated TFPI and conﬁrmed that
TFPI chromogenic activity is strongly associated with TFPI
total antigen [19].
43210–1–2–3
1.3A
B
C
D
1.2
1.1
1.0
0.9
0.8
TFPI free antigen (z-score) 
n
-T
FP
Ia
c 
ra
tio
n
-T
FP
Ia
c 
ra
tio
n
-T
FP
Ia
c 
ra
tio
43210–1–2–3
1.3
1.2
1.1
1.0
0.9
0.8
TFPI total antigen (z-score)
43210–1–2–3
1.3
1.2
1.1
1.0
0.9
0.8
TFPI chrom. subst. act. (z-score) 
43210–1–2–3
1.3
1.2
1.1
1.0
0.9
0.8
n
-T
FP
Ia
c 
ra
tio
Bound TFPI (z-score)
Fig. 4. Scatter plots with linear regression lines. The dependent variable
(y-axis) is the normalized TFPI anticoagulant (n-TFPIac) ratio in all
four plots. The independent variable (x-axis) is expressed as the number of
standard deviations from the mean (z-score) and is TFPI free antigen
(A), TFPI total antigen (B), TFPI chromogenic substrate activity (C),
and bound TFPI (D).
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Mechanistically, the difference between the two activity
assays may be attributed to the reaction kinetics between TFPI
and its target proteases. TFPI is both an inhibitor of FXa and
of the TF/FVIIa catalytic complex. Inhibition is thought to
occur in two steps, ﬁrst the binding of the second TFPI Kunitz
domain to FXa, which results in functional inhibition of FXa,
and in a second step, binding of the ﬁrst TFPI Kunitz domain
of the TFPI/FXa complex to FVIIa of the TF/FVIIa complex
[1]. This results in the formation of a catalytically inactive
quaternary TFPI/FXa/TF/FVIIa complex.
Binding of TFPI to FXa is the rate-limiting step [31]. Free,
full-length TFPI binds to and inhibits FXa at a several-fold
higher rate than truncated or lipoprotein-associated TFPI
[1,32], which is attributed to the conserved C-terminal end of
full-length TFPI [1,33]. Once formed, the TFPI/FXa complex
inhibits TF/FVIIa catalytic activity with similar efﬁciency
irrespective of the nature of the TFPI, i.e. truncated or full-
length TFPI, incorporated in the TFPI/FXa complex [1,31]. In
the DPT assay used for assay of n-TFPIac activity, clotting
occurs within approximately 75 s after the addition of a small
amount of TF, and reaction velocities then play an important
role for anticoagulant activity. TFPI cannot inhibit TF/VIIa
until some FXa has been generated. TFPI/FXa complexes are
formed more rapidly with free, full-length TFPI than with
truncated and lipoprotein-associated TFPI, which allows more
rapid and efﬁcient inhibition of TF/FVIIa and consequently
prolonged clotting time. TFPI anticoagulant activity may
therefore be considered a kinetic assay and to a large extent
dependent on the initial inhibition of FXa [34,35].
In the TFPI chromogenic substrate activity assay TF, FVIIa
and FXa are added to plasma containing TFPI and incubated
for approximately 30 min, which allows near-equilibrium
conditions for the inhibition of TF/FVIIa. This means that
full-length TFPI and the different forms of TFPI are all
allowed to form complexes with FXa irrespective of the
reaction velocities. The TFPI chromogenic substrate assay is
therefore functionally an end-point or equilibrium assay, which
cannot distinguish the ability of different TFPI molecules to
inhibit FXa and the TF/FVIIa. TFPI chromogenic substrate
assay may also be considered a capacity assay because it
correlates well with TFPI total antigen.
We conclude that the present TFPI anticoagulant activity
assay primarily measures the effect of full-length TFPI and is
essentially insensitive to truncated TFPI. TFPI anticoagulant
activity can therefore be considered an activity-assay of free,
full-length TFPI. Further studies are needed to determine the
role of TFPI anticoagulant activity in vivo, and whether TFPI
anticoagulant activity should replace one or more current
assays for the measurement of TFPI in plasma samples from
patients with thrombosis.
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Table 1 The association of normalized TFPI anticoagulant ratio to
other TFPI assays
TFPI assay
Normalized TFPI
anticoagulant ratio
b (95% CI)
Correlation
coeﬃcient
r
TFPI free antigen 0.049 (0.044–0.053) 0.73
Total TFPI 0.033 (0.027–0.038) 0.48
TFPI activity 0.031 (0.025–0.037) 0.46
Bound TFPI 0.020 (0.014–0.026) 0.30
Standardized regression coeﬃcient (b), 95% conﬁdence interval (CI)
and correlation coeﬃcient (r). (b) shows the change in n-TFPIac ratio
per increase of one standard deviation in the TFPI assay studied.
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